Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI

Nicola Jane Mutch, N R Moore, E Wang, N A Booth

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The carboxypeptidase, TAFIa or CPU, is known to prolong plasma clot lysis by tissue plasminogen activator (tPA) and to have a role in thrombus stability in vivo. This current study examined lysis by urokinase (uPA) and single chain urokinase (scuPA) in addition to tPA. Further, we investigated the role of TAFIa in a model thrombus system, in which thrombi are formed under conditions of flow. We show that human thrombi, formed in vivo, and model thrombi both contain TAFI. No effect of thrombus TAFIa was observed in thrombus lysis assays, except when thrombi were bathed in plasma, in which case addition of potato tuber carboxypeptidase inhibitor (CPI) resulted in doubling of the rate of lysis. TAFIa inhibited lysis of model thrombi and plasma clots by uPA, scuPA in addition to lysis by tPA. The effect of TAFIa was more evident at high concentrations of plasminogen activator such as those used in thrombolytic therapy. Addition of plasminogen increased lysis and, in its presence, the enhancement by CPI was smaller. Thus the action of TAFIa could be partially overcome by plasminogen, whether lysis was by tPA, uPA or scuPA. This is consistent with TAFIa exerting its effect primarily through modifying the binding of plasminogen to fibrin and to a lesser extent through modification of the binding of tPA to fibrin.
Original languageEnglish
Pages (from-to)2000-2007
Number of pages8
JournalJournal of Thrombosis and Haemostasis
Volume1
Issue number9
DOIs
Publication statusPublished - 1 Sep 2003

Fingerprint

Tissue Plasminogen Activator
Thrombosis
Carboxypeptidases
Plasminogen
Urokinase-Type Plasminogen Activator
Fibrin
Plasminogen Activators
Thrombolytic Therapy
Solanum tuberosum

Keywords

  • Carboxypeptidase U
  • Fibrin
  • Fibrinolysis
  • Humans
  • Kinetics
  • Models, Biological
  • Plasminogen
  • Protein Binding
  • Thrombolytic Therapy
  • Thrombosis
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator

Cite this

Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. / Mutch, Nicola Jane; Moore, N R; Wang, E; Booth, N A.

In: Journal of Thrombosis and Haemostasis, Vol. 1, No. 9, 01.09.2003, p. 2000-2007.

Research output: Contribution to journalArticle

@article{b6b19bcd15e54fbe813a0e035f620d04,
title = "Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI",
abstract = "The carboxypeptidase, TAFIa or CPU, is known to prolong plasma clot lysis by tissue plasminogen activator (tPA) and to have a role in thrombus stability in vivo. This current study examined lysis by urokinase (uPA) and single chain urokinase (scuPA) in addition to tPA. Further, we investigated the role of TAFIa in a model thrombus system, in which thrombi are formed under conditions of flow. We show that human thrombi, formed in vivo, and model thrombi both contain TAFI. No effect of thrombus TAFIa was observed in thrombus lysis assays, except when thrombi were bathed in plasma, in which case addition of potato tuber carboxypeptidase inhibitor (CPI) resulted in doubling of the rate of lysis. TAFIa inhibited lysis of model thrombi and plasma clots by uPA, scuPA in addition to lysis by tPA. The effect of TAFIa was more evident at high concentrations of plasminogen activator such as those used in thrombolytic therapy. Addition of plasminogen increased lysis and, in its presence, the enhancement by CPI was smaller. Thus the action of TAFIa could be partially overcome by plasminogen, whether lysis was by tPA, uPA or scuPA. This is consistent with TAFIa exerting its effect primarily through modifying the binding of plasminogen to fibrin and to a lesser extent through modification of the binding of tPA to fibrin.",
keywords = "Carboxypeptidase U, Fibrin, Fibrinolysis, Humans, Kinetics, Models, Biological, Plasminogen, Protein Binding, Thrombolytic Therapy, Thrombosis, Tissue Plasminogen Activator, Urokinase-Type Plasminogen Activator",
author = "Mutch, {Nicola Jane} and Moore, {N R} and E Wang and Booth, {N A}",
year = "2003",
month = "9",
day = "1",
doi = "10.1046/J.1538-7836.2003.00383.X",
language = "English",
volume = "1",
pages = "2000--2007",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI

AU - Mutch, Nicola Jane

AU - Moore, N R

AU - Wang, E

AU - Booth, N A

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The carboxypeptidase, TAFIa or CPU, is known to prolong plasma clot lysis by tissue plasminogen activator (tPA) and to have a role in thrombus stability in vivo. This current study examined lysis by urokinase (uPA) and single chain urokinase (scuPA) in addition to tPA. Further, we investigated the role of TAFIa in a model thrombus system, in which thrombi are formed under conditions of flow. We show that human thrombi, formed in vivo, and model thrombi both contain TAFI. No effect of thrombus TAFIa was observed in thrombus lysis assays, except when thrombi were bathed in plasma, in which case addition of potato tuber carboxypeptidase inhibitor (CPI) resulted in doubling of the rate of lysis. TAFIa inhibited lysis of model thrombi and plasma clots by uPA, scuPA in addition to lysis by tPA. The effect of TAFIa was more evident at high concentrations of plasminogen activator such as those used in thrombolytic therapy. Addition of plasminogen increased lysis and, in its presence, the enhancement by CPI was smaller. Thus the action of TAFIa could be partially overcome by plasminogen, whether lysis was by tPA, uPA or scuPA. This is consistent with TAFIa exerting its effect primarily through modifying the binding of plasminogen to fibrin and to a lesser extent through modification of the binding of tPA to fibrin.

AB - The carboxypeptidase, TAFIa or CPU, is known to prolong plasma clot lysis by tissue plasminogen activator (tPA) and to have a role in thrombus stability in vivo. This current study examined lysis by urokinase (uPA) and single chain urokinase (scuPA) in addition to tPA. Further, we investigated the role of TAFIa in a model thrombus system, in which thrombi are formed under conditions of flow. We show that human thrombi, formed in vivo, and model thrombi both contain TAFI. No effect of thrombus TAFIa was observed in thrombus lysis assays, except when thrombi were bathed in plasma, in which case addition of potato tuber carboxypeptidase inhibitor (CPI) resulted in doubling of the rate of lysis. TAFIa inhibited lysis of model thrombi and plasma clots by uPA, scuPA in addition to lysis by tPA. The effect of TAFIa was more evident at high concentrations of plasminogen activator such as those used in thrombolytic therapy. Addition of plasminogen increased lysis and, in its presence, the enhancement by CPI was smaller. Thus the action of TAFIa could be partially overcome by plasminogen, whether lysis was by tPA, uPA or scuPA. This is consistent with TAFIa exerting its effect primarily through modifying the binding of plasminogen to fibrin and to a lesser extent through modification of the binding of tPA to fibrin.

KW - Carboxypeptidase U

KW - Fibrin

KW - Fibrinolysis

KW - Humans

KW - Kinetics

KW - Models, Biological

KW - Plasminogen

KW - Protein Binding

KW - Thrombolytic Therapy

KW - Thrombosis

KW - Tissue Plasminogen Activator

KW - Urokinase-Type Plasminogen Activator

U2 - 10.1046/J.1538-7836.2003.00383.X

DO - 10.1046/J.1538-7836.2003.00383.X

M3 - Article

VL - 1

SP - 2000

EP - 2007

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -